Judge Lets Most Of Xyrem Antitrust Suit Against Jazz Survive
By Bryan Koenig · August 17, 2021, 11:19 PM EDT
A California federal judge has largely refused to dismiss antitrust multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anticompetitive...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login